MBX Biosciences Stock Forecast
NASDAQ: MBXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MBX analyst consensus
Consensus (12 analysts)
strong_buy
Avg. price target
$95.09+91.91%
- Strong buy 3
- Buy 9
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 12 Wall Street analysts covering MBX Biosciences (2026-11-19), 12 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $95.09, with a high estimate of $150.00 and a low estimate of $80.00. The average target implies upside of 91.9% from the current price of $49.55.
The spread between the highest and lowest targets is 87.5%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for MBX.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 25% |
| Buy | 9 | 75% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-11-19.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $80.00 | +61.45% |
| Average target | $95.09 | +91.91% |
| High target | $150.00 | +202.72% |